Amsacrine

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Amsacrine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1987. DrugCentral lists 9 molecular targets, including TOP1, TOP1MT and KCNH2.

• Molecular targets: TOP1, TOP1MT, KCNH2 and TOP2A|TOP2B (9 listed in DrugCentral).
• ATC code: L01XX01 (Other antineoplastic agents).
• Molecular formula: C21H19N3O3S; molecular weight 393.46 g/mol.

Mechanism & targets

Molecular targets (9)

Target	Gene	Action	Activity
DNA topoisomerase 1	TOP1	unknown	IC50 7.43
DNA topoisomerase I, mitochondrial	TOP1MT	unknown	IC50 7.43
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 6.68
DNA topoisomerase II	TOP2A|TOP2B	unknown	EC50 6.14
Lysine-specific histone demethylase 1A	KDM1A	unknown	IC50 6.06
Solute carrier family 22 member 1	SLC22A1	unknown	IC50 5.30
Cytochrome P450 2D6	CYP2D6	unknown	Ki 5.12
DNA topoisomerase 2-alpha	TOP2A	unknown	IC50 5.00
DNA topoisomerase 2-beta	TOP2B	unknown	EC50 4.96

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1987-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
L01XX01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Acute myeloid leukaemia recurrent	194.1
Venoocclusive liver disease	183.3
Drug resistance	141.1
Graft versus host disease	134.6
Graft versus host disease in gastrointestinal tract	114.4
Dysbiosis	106.9
Multiple organ dysfunction syndrome	102.0
Systemic inflammatory response syndrome	96.9
Septic shock	93.3
Cerebral toxoplasmosis	88.4
Bronchopulmonary aspergillosis	88.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Amsacrine is on its molecule page.

• Molecular formula: C₂₁H₁₉N₃O₃S
• Molecular weight: 393.46 g/mol
• CAS number: 51264-14-3
• InChIKey: XCPGHVQEEXUHNC-UHFFFAOYSA-N
• PubChem CID: 2179

COC1=C(NC2=C3C=CC=CC3=NC3=CC=CC=C23)C=CC(NS(C)(=O)=O)=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Amsacrine work?

Its molecular targets in DrugCentral include TOP1, TOP1MT, KCNH2 and TOP2A|TOP2B.

When was Amsacrine first approved?

Amsacrine was first approved by the YEAR INTRODUCED in 1987.

What is the chemical formula of Amsacrine?

Amsacrine has the molecular formula C21H19N3O3S and a molecular weight of 393.46 g/mol.

Sources

• DrugCentral drug card 203 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL43 — compound record and bioactivity
• PubChem CID 2179 — chemical identifiers
• DrugBank DB00276 — drug record
• FDA UNII 00DPD30SOY — substance identity
• UniProt P11387 (TOP1) — target protein
• UniProt Q969P6 (TOP1MT) — target protein
• UniProt Q12809 (KCNH2) — target protein
• UniProt O60341 (KDM1A) — target protein
• UniProt O15245 (SLC22A1) — target protein
• UniProt P10635 (CYP2D6) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.